"The study, published in the Journal of the Endocrine Society earlier this year, looked into the effects different methods of applying feminising hormone therapy had on patients. Endocrinologists analysed data sets from an academic centre published from 2017 to 2023, which tested the effects of injectable estradiol dosing. 29 patients switched from traditional forms of estradiol treatment, such as gels or tablets, to weekly injections, and were analysed over 15 months. The average weekly estradiol dose was also lowered from 4.3 to 3.7mg."
"Researchers discovered that, remarkably, every single patient saw a dramatic drop in their testosterone levels despite the lower dose, while estrogen levels weren't affected. Comparitevly, they found that Spironolactone - the most commonly prescribed anti-androgen drug which aims to block testosterone production - was not associated with a lower initial on-treatment testosterone level. In fact, researchers suggested the prescription drug could cause lower estradiol levels compared to those only taking injectable estradiol."
Data sets from an academic centre covering 2017–2023 examined injectable estradiol dosing and method of administration. Twenty-nine patients switched from gels or tablets to weekly estradiol injections and were followed for 15 months, with average weekly estradiol falling from 4.3 to 3.7 mg. Every patient experienced a substantial decline in testosterone despite the lower estradiol dose, while estrogen levels remained stable. Spironolactone was not linked to additional testosterone suppression and may lower estradiol. Spironolactone use has been associated with fatigue, dizziness, increased urination, and rare electrolyte, kidney, and liver issues. Findings imply injectable estradiol monotherapy could enable lower doses with effective testosterone suppression and influence HRT prescribing practices.
Read at PinkNews | Latest lesbian, gay, bi and trans news | LGBTQ+ news
Unable to calculate read time
Collection
[
|
...
]